WO2001053456A3 - Methods and materials relating to prothrombinase-like polypeptides and polynucleotides - Google Patents
Methods and materials relating to prothrombinase-like polypeptides and polynucleotides Download PDFInfo
- Publication number
- WO2001053456A3 WO2001053456A3 PCT/US2000/035061 US0035061W WO0153456A3 WO 2001053456 A3 WO2001053456 A3 WO 2001053456A3 US 0035061 W US0035061 W US 0035061W WO 0153456 A3 WO0153456 A3 WO 0153456A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- polynucleotides
- polypeptides
- prothrombinase
- methods
- seq
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6432—Coagulation factor Xa (3.4.21.6)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21006—Coagulation factor Xa (3.4.21.6)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Wood Science & Technology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
Abstract
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU25936/01A AU783762B2 (en) | 1999-12-23 | 2000-12-22 | Methods and materials relating to prothrombinase-like polypeptides and polynucleotides |
CA002395749A CA2395749A1 (en) | 1999-12-23 | 2000-12-22 | Methods and materials relating to prothrombinase-like polypeptides and polynucleotides |
EP00989432A EP1240178A4 (en) | 1999-12-23 | 2000-12-22 | Methods and materials relating to prothrombinase-like polypeptides and polynucleotides. |
US10/311,827 US20050175994A1 (en) | 1999-01-20 | 2000-12-22 | Methods and materials relating to prothrombinase-like polypeptides and polynucleotides |
JP2001553917A JP2004508804A (en) | 2000-01-21 | 2000-12-22 | Methods and materials for prothrombinase-like polypeptides and polynucleotides |
Applications Claiming Priority (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47127599A | 1999-12-23 | 1999-12-23 | |
US09/471,275 | 1999-12-23 | ||
US48872500A | 2000-01-21 | 2000-01-21 | |
US09/488,725 | 2000-01-21 | ||
US49140400A | 2000-01-25 | 2000-01-25 | |
US09/491,404 | 2000-01-25 | ||
US55231700A | 2000-04-25 | 2000-04-25 | |
US09/552,317 | 2000-04-25 | ||
US09/596,196 | 2000-06-17 | ||
US09/596,196 US6586390B1 (en) | 2000-01-21 | 2000-06-17 | Methods and materials relating to novel prothrombinase-like polypeptides and polynucleotides |
US64331300A | 2000-08-31 | 2000-08-31 | |
US09/653,274 US6635742B1 (en) | 2000-01-25 | 2000-08-31 | Antibodies specific for semaphorin-like polypeptides |
US09/643,313 | 2000-08-31 |
Publications (4)
Publication Number | Publication Date |
---|---|
WO2001053456A2 WO2001053456A2 (en) | 2001-07-26 |
WO2001053456A3 true WO2001053456A3 (en) | 2002-05-30 |
WO2001053456A8 WO2001053456A8 (en) | 2002-07-04 |
WO2001053456A9 WO2001053456A9 (en) | 2002-12-05 |
Family
ID=27560029
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/035061 WO2001053456A2 (en) | 1999-01-20 | 2000-12-22 | Methods and materials relating to prothrombinase-like polypeptides and polynucleotides |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1240178A4 (en) |
AU (1) | AU783762B2 (en) |
CA (1) | CA2395749A1 (en) |
WO (1) | WO2001053456A2 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002224056A1 (en) | 2000-11-22 | 2002-06-03 | Yamanouchi Pharmaceutical Co..Ltd. | Novel polypeptide |
CA2399569A1 (en) | 2001-09-25 | 2003-03-25 | Yusuke Nakamura | Diagnostic markers and drug targets for treatment of cancer |
AU2002329061A1 (en) | 2001-09-25 | 2003-04-07 | Japan As Represented By The President Of The University Of Tokyo | Gene and protein relating to hepatocellular carcinoma |
CA2497337A1 (en) * | 2002-09-11 | 2004-03-25 | Genentech, Inc. | Novel composition and methods for the treatment of psoriasis |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001005825A2 (en) * | 1999-07-16 | 2001-01-25 | Hyseq, Inc. | Nucleic acid sequences encoding putative angiopoietin proteins |
-
2000
- 2000-12-22 AU AU25936/01A patent/AU783762B2/en not_active Ceased
- 2000-12-22 WO PCT/US2000/035061 patent/WO2001053456A2/en active Search and Examination
- 2000-12-22 CA CA002395749A patent/CA2395749A1/en not_active Abandoned
- 2000-12-22 EP EP00989432A patent/EP1240178A4/en not_active Withdrawn
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001005825A2 (en) * | 1999-07-16 | 2001-01-25 | Hyseq, Inc. | Nucleic acid sequences encoding putative angiopoietin proteins |
Non-Patent Citations (5)
Title |
---|
DATABASE GENEMBL [online] COMPUGEN LTD.; BALLINGER ET AL.: "Novel angiopoietin materials and methods", XP002944228, accession no. GenCore Database accession no. AX079973 * |
DATABASE GENEMBL [online] COMPUGEN LTD.; March 2000 (2000-03-01), BIRREN ET AL.: "Homo sapiens, clone RP11-21G19, direct submission", XP002944227, accession no. GenCore Database accession no. AC015500 * |
GALE ET AL.: "Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins and ephrins in vascular development", GENES & DEV., vol. 13, 1999, pages 1055 - 1066, XP002944219 * |
LEVY ET AL.: "Molecular and functional analysis of the human prothrombinase gene (HFGL2) and its role in viral hepatitis", AM. J. PATH., vol. 156, no. 4, April 2000 (2000-04-01), pages 1217 - 1225, XP002944220 * |
See also references of EP1240178A4 * |
Also Published As
Publication number | Publication date |
---|---|
EP1240178A2 (en) | 2002-09-18 |
WO2001053456A2 (en) | 2001-07-26 |
AU2593601A (en) | 2001-07-31 |
CA2395749A1 (en) | 2001-07-26 |
AU783762B2 (en) | 2005-12-01 |
WO2001053456A8 (en) | 2002-07-04 |
WO2001053456A9 (en) | 2002-12-05 |
EP1240178A4 (en) | 2004-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001088092A3 (en) | Methods and materials relating to stem cell factor-like (scf-like) polypeptides and polynucleotides | |
CA2343715A1 (en) | New human growth differentiation factor encoding sequence and polypeptide encoded by such dna sequence and producing method thereof | |
WO2001055336A3 (en) | Methods and materials relating to cd84-like polypeptides and polynucleotides | |
EP1308459A3 (en) | Full-length cDNA sequences | |
WO2001077169A3 (en) | Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides | |
CA2318030A1 (en) | Acpl dna and polypeptides | |
WO2001053454A3 (en) | Methods and materials relating to g protein-coupled receptor-like polypeptides and polynucleotides | |
IL141869A0 (en) | Mammalian transforming growth factor beta-9 (ztgfss9) | |
WO2003029405A3 (en) | Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides | |
WO2001055335A3 (en) | Methods and materials relating to leukocyte immunoglobulin receptor-like (lir-like) polypeptides and polynucleotides | |
EP1574520A3 (en) | Methods and materials relating to neuronal guidance molecule-like (NGM-like) polypeptides and polynucleotides | |
WO2001053456A8 (en) | Methods and materials relating to prothrombinase-like polypeptides and polynucleotides | |
EP0759470A3 (en) | Gene encoding endoglycoceramidase activator | |
WO2001053500A8 (en) | Methods and materials relating to stem cell growth factor-like poypeptides and polynucleotides | |
WO2001075064A3 (en) | Method and materials relating to insulin-like growth factor binding protein-like polypeptides and polynucleotides | |
WO2001055337A3 (en) | Methods and materials relating to carcinoembryonic antigen-like (cea-like) polypeptides and polynucleotides | |
WO2001055333A8 (en) | Methods and materials relating to transforming growth factor alpha-like polypeptides and polynucleotides | |
WO2001057233A3 (en) | Methods and materials relating to preadipocyte factor-1-like (pref-1-like) polypeptides and polynucleotides | |
WO2001055332A3 (en) | Methods and materials relating to novel growth regulatory-like polypeptides and polynucleotides | |
WO2001055435A3 (en) | Methods and materials relating to hematopoietic cytokine-like polypeptides and polynucleotides | |
WO2003040326A3 (en) | Methods and materials relating to prokineticin-like polypeptides and polynucleotides | |
WO2001057175A3 (en) | Methods and materials relating to neurotrimin-like polypeptides and polynucleotides | |
EP0801133A3 (en) | Hydroperoxide lyases | |
WO2000004041A3 (en) | Methods and molecules relating to cd39-like polypeptides | |
WO2001029224A3 (en) | Granulocyte peptide homolog zgpa1 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US US US US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US US US US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2395749 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000989432 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 553917 Kind code of ref document: A Format of ref document f/p: F |
|
AK | Designated states |
Kind code of ref document: C1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US US US US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: C1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
CFP | Corrected version of a pamphlet front page | ||
WWE | Wipo information: entry into national phase |
Ref document number: 25936/01 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2000989432 Country of ref document: EP |
|
AK | Designated states |
Kind code of ref document: C2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US US US US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: C2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10311827 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWG | Wipo information: grant in national office |
Ref document number: 25936/01 Country of ref document: AU |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000989432 Country of ref document: EP |
|
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) |